This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Treatment-Resistant Depression Treatment Market

Market Insights on Treatment-Resistant Depression Treatment covering sales outlook, demand forecast & up-to-date key trends

Treatment-Resistant Depression Treatment Market by Drug Type, Distribution Channel & Region – Forecast 2023–2033

Treatment-Resistant Depression Treatment Market Snapshot (2023-2033)

The global treatment-resistant depression treatment market size is expected to be valued at US$ 1.69 Billion in 2023. With the increasing prevalence of depression and anxiety disorders in adults, coupled with the aging population, the overall demand for Treatment-Resistant Therapeutics Treatment is projected to grow at a CAGR of 9.0% between 2023 and 2033, totaling around US$ 4.0 Billion by 2033.

The rising occurrence of Treatment-Resistant Depression has generated consciousness regarding its treatment. Various market players are developing advanced drugs that can be administered through nasal and intravenous routes rather than the traditional oral route of administration. The traditional antidepressants used for this disorder treatment require at least 4-6 weeks to produce an effect with a risk of incomplete or poor outcomes through the oral route of administration, whereas the intranasal has been found to produce better results within hours of administration.

For instance, in January 2022, as per the article published by Pharmacopsychiatry, the novel pipeline antidepressant MIJ821 of Novartis Pharmaceuticals demonstrated a more significant reduction in depressive episodes within 24 hours of administration via infusion weekly among patients.

In addition, the overall findings displayed that treatment with intranasal esketamine in amalgamation with a novel oral antidepressant was more efficient than a placebo plus an oral administration. The intranasal esketamine showcased a prompt drop of depressive symptoms and postponed its relapse time. Such increasing research & development for advanced drugs through other routes of administration is projected to surge the demand for drugs, thereby augmenting the overall market growth.

Data Points

Key Statistics

Treatment-Resistant Depression Therapeutics Market Value 2023

US$ 1.69 Billion

Treatment-Resistant Depression Therapeutics Market Projected Value (2033)

US$ 4.0 Billion

Treatment-Resistant Depression Therapeutics Market CAGR (2023-2033)

9.0%

Customize this Report

Let us know your requirement to get
100% FREE customization

Treatment-Resistant Depression Treatment Demand Analysis (2018 to 2022) Vs Market Outlook (2023 to 2033)

The global demand for treatment-resistant depression therapeutics is projected to increase at a CAGR of 9.0% during the forecast period between 2023 and 2033, reaching a total of US$ 4.0 Billion in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 3.3%.

According to Future Market Insights, a market research and competitive intelligence provider, the Treatment-Resistant Depression Therapeutics market was valued at US$ 1.55 Billion in 2022. As per the World Health Organization (WHO), prevalence of mental health disorders as well as conditions is increasing across the globe. There has been a 13% increase in mental health conditions and other depressive disorders in the last decade.

According to the U.S. Department of Health and Human Services (HHS), in 2020, among adolescents between ages 12 and 17, 17.0% (about 4.1 million population) had major depressive episode (MDE), and 12% (about 2.9 million people) had MDE with severe impairment. Moreover, several factors such as demographic changes, environmental conditions, and increasing mental stress are resulting in rising mental health disorders. This is improving the growth in depression treatment market.

Which Drivers underpin Treatment-Resistant Depression Treatment Industry Expansion?

Increasing Drug Development Projects to Fuel the Market Growth

The rise in the prevalence of Treatment-Resistant Depression and the presence of few treatment options has stimulated the market players to initiate full-fledged research and development activities. Various major market players are focusing on developing new and innovative therapies in the market, citing the clinical benefits and a significant unmet need in treating the disorder globally.

Additionally, it is the leading cause of worldwide disability as conventional therapies are ineffective in a large patient pool, and novel therapies are needed to cater to this growing demand. Also, various pharmaceutical as well as life science companies are actively investing in clinical trials of potential pipeline candidates to introduce novel products for treatment. Further, such active participation from the public and private players in developing potential candidates under investigational studies to escalate the demand for resistant depression treatment around the globe.

Increasing Prevalence of TRD Globally to Accelerate the Market Growth

The increase in the prevalence of this mood disorder is one of the major factors that is projected to boost the growth of the TRD Treatment market. TRD occurs when an individual hasn't responded to doses of two different antidepressants taken for an adequate time, usually six weeks. The increase in the prevalence of this medical condition has increased the demand for the resistant depression therapeutics.

In addition, according to Springer's research article published in August 2021, major depression disorders affect over 300 million people worldwide, and approximately one-third of patients with MDD have treatment-resistant depression. The prevalence is also associated with disproportionate healthcare costs that have significant direct and indirect cost implications, which places considerable strain on healthcare and social resources.

The variability in the type of healthcare setting as well as accessibility to quality healthcare across the countries to assess unmet needs and treatment failure increases the demand for effective therapeutic measures. Such a rising prevalence of this disorder and disproportionate healthcare costs, which varies across the globe, are anticipated to surge the demand for an effective treatment thereby, fostering the overall treatment growth over the analysis period.

Sabyasachi Ghosh
Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Which Factors are limiting the Growth of Treatment-Resistant Depression Treatment Market?

Poor Management of Disorders to Restrain the Market Growth

Despite increasing investment from market players in the TRD project for developing an effective therapeutic measure, there is poor management of this mood disorder, resulting in significant variations in how patients are being managed in real-world practice.

Moreover, the lack of clarity in diagnosing patients is a significant challenge for its treatment. Patients drop out or discontinue treatment due to poor or no positive outcomes. In addition, a cultural and social stigma toward reporting non-responsiveness to treatment, lack of therapeutic options, and inadequate guidelines for managing patients are cumulatively responsible for restraining the market growth.

According to a December 2020 study published by NIH, for management of TRD, 41.0% of physicians reported treatment discontinuation and loss to follow-up as the top challenge, while 15.0% indicated a lack of therapeutic options as their biggest challenge. Another 14.0% and 13.0% were related to a lack of standardized TRD definition and specific guidelines, respectively. In addition, lack of clarity in guidelines for diagnosis and management of this mood disorder patients, coupled with limited therapeutic measures is expected to hinder the market growth over the analysis period.

Region-wise Insights

Will North America Continue Dominance in the Global Treatment-Resistant Depression Treatment Market?

Advanced Healthcare Infrastructure in the Region to Fuel the Market Growth

The treatment-resistant depression therapeutics market in North America is expected to accumulate the highest market share of 50% in 2023. North America is the most lucrative region along with the highest market share. Factors such as the advanced healthcare infrastructure and healthcare spending are anticipated to fuel the growth of the Treatment-Resistant Depression Market during the forecast period. Also, increasing the adoption rate and demand will propel the treatment-resistance depression treatment market in this region.

In addition, in recent years, there has been a growing rate of adoption and increasing demand for treatment resistant depression is also expected to drive the regional market. The region is expected to hold the highest CAGR of 8.8% during the forecast period.

How Will Growth of the Treatment-Resistant Depression Treatment Market unfold in Asia Pacific?

Growing Awareness Regarding Mental Disorders in the Region to Fuel the Market Growth

The treatment-resistant depression therapeutics market in Asia Pacific is expected to accumulate the highest market share of 49% in 2023. APAC is the most lucrative region along with the highest market share.

Asia Pacific is opening up the previously held taboo of mental health. With growing awareness about mental disorders, depression, and mental health, the regional segment of Asia Pacific is expected to show a promising rate of growth and give rise to lucrative business opportunities for the development of the market in coming years. The region is expected to hold the highest CAGR of 8.7% during the forecast period.

MarketNage
Become a MarketNgage Insider

A unified Market Research Subscription Platform, built for today's disparate research needs.

Category-wise Insights

By Drug Type, which Treatment-Resistant Depression Treatment Category will remain prominent?

NMDA Segment to beat Competition in Untiring Market

On the basis of drug type, the global Treatment-Resistant Depression Therapeutics market is dominated by NMDA Segment, which accounts for a share of 49%. The growth of the NMDA segment is attributed to the increasing research studies for developing NMDA drugs to improve treatment outcomes.

Moreover, the larger patient population suffering from this disorder and FDA approval of NMDA drugs developed by the key market are expected to fuel the segmental growth in the coming years. The segment is expected to hold a CAGR of 8.8% over the analysis period.

By Distribution Channel, which Treatment-Resistant Depression Treatment Category to dominate?

Hospital Pharmacies Segment to Drive the Treatment-Resistant Depression Therapeutics Market

Based on the Distribution Channel, the hospital pharcies segment is expected to witness a significant growth of 47% in 2022, and the trend is expected to continue during the forecast period.

In the treatment of this mood disorder, a prescription for drugs from a medical professional is needed, this is a crucial reason attributable to the segment's growth. In addition, the expansion of hospital pharmacies owing to increasing investment by the public sector in the healthcare infrastructure in emerging countries is predicted to augment the segmental growth during the forecast period. The segment is expected to hold a CAGR of 8.7% over the analysis period.

Who are the Leading Players in the Treatment-Resistant Depression Treatment Market?

Prominent players in the treatment-resistant depression therapeutics market are Janssen Global Services, LLC, AbbVie Inc., Sandoz International GmbH (Novartis AG), H. Lundbeck A/S, Par Pharmaceutical (Endo International plc), Otsuka Pharmaceutical Co., Ltd., and AstraZeneca, among others.

Recent Developments:

  • In August 2022, Merck Sharp & Dohme LLC initiated Phase II A Clinical Trial to evaluate the safety and efficacy of MK-1942 among treatment-resistant depression patients.
  • In July 2022, Novartis Pharmaceuticals announced that it would initiate a Phase 2 clinical trial of MIJ821 (ketamine) for treatment-resistant depressive disorders in September 2022.
  • In May 2022, COMPASS Pathways presented positive data for Phase IIb study of COMP360 psilocybin therapy for treatment-resistant depression treatment at the American Psychiatric Association annual meeting in New Orleans.
  • In February 2022, Denova Biopharma secured U.S. FDA approval to initiate a Phase 2b clinical trial to analyze the efficacy and safety of DB104 (liafensine) in patients with treatment-resistant mood disorder.

Report Scope

Report Attribute

Details

Growth Rate

CAGR of 9% from 2023-2033

Market Value in 2023

US$ 1.69 Billion

Market Value in 2033

US$ 4 Billion

Base Year for Estimation

2022

Historical Data

2018-2022

Forecast Period

2023-2033

Quantitative Units

Revenue in US$ Billion and CAGR from 2023-2033

Report Coverage

Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis

Segments Covered

  • Drug Type
  • Distribution Channel
  • Region

Regions Covered

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa (MEA)

Key Countries Profiled

  • U.S
  • Canada
  • Brazil
  • Mexico
  • Germany
  • U.K
  • France
  • Spain
  • Italy
  • China
  • Japan
  • South Korea
  • India
  • Malaysia
  • Singapore
  • Thailand
  • Australia
  • New Zealand
  • GCC
  • South Africa
  • Israel

Key Companies Profiled

  • Eli Lilly and Company
  • GlaxoSmithKline
  • Pfizer Inc.
  • Janssen Pharmaceuticals
  • AbbVie Inc.
  • AstraZeneca
  • H. Lundbeck A/S
  • Sandoz International GmbH
  • Par Pharmaceutical Companies Inc.
  • Otsuka Holdings Co., Ltd.

Customization & Pricing

Available upon Request

Key Segments Covered in the Treatment-Resistant Depression Treatment Industry Analysis

Treatment-Resistant Depression Treatment Market by Drug Type:

  • NMDA
  • Antidepressants
  • Antipsychotics
  • Others

Treatment-Resistant Depression Therapeutics Market by Distribution Channel:

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

Treatment-Resistant Depression Treatment Market by Region:

  • North America
  • Latin America
  • Europe
  • South Asia & Pacific
  • East Asia
  • Middle East & Africa

Frequently Asked Questions

As of 2022, the market for Treatment-Resistant Depression Treatment was valued at US$ 1.55 Billion, as per FMI

By 2023-end, demand for treatment-resistant depression treatment closed at a value of US$ 1.69 Billion

From 2018 to 2022, Treatment-Resistant Depression Treatment demand expanded at a CAGR of 3.3%

From 2023 to 2033, treatment-resistant depression treatment demand is expected to flourish at a CAGR of 9%

By 2033, the market value of treatment-resistant depression treatment is expected to reach US$ 4 Billion

By drug type, the NMDA segment of the treatment-resistant depression treatment constitutes the bulk of market share of 49% in 2022

By distribution channel, the hospital pharmacies segment dominates the market with a share of 47% in 2022.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018-2022 and Forecast, 2023-2033

    4.1. Historical Market Size Value (US$ Bn) Analysis, 2018-2022

    4.2. Current and Future Market Size Value (US$ Bn) Projections, 2023-2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Drug Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Bn) Analysis By Drug Type, 2018-2022

    5.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By Drug Type, 2023-2033

        5.3.1. NMDA

        5.3.2. Antidepressants

        5.3.3. Antipsychotics

        5.3.4. Other Drug Types

    5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2018-2022

    5.5. Absolute $ Opportunity Analysis By Drug Type, 2023-2033

6. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Distribution Channel

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Bn) Analysis By Distribution Channel, 2018-2022

    6.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By Distribution Channel, 2023-2033

        6.3.1. Hospital Pharmacies

        6.3.2. Drug Stores & Retail Pharmacies

        6.3.3. Online Pharmacies

    6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018-2022

    6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023-2033

7. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Region

    7.1. Introduction

    7.2. Historical Market Size Value (US$ Bn) Analysis By Region, 2018-2022

    7.3. Current Market Size Value (US$ Bn) Analysis and Forecast By Region, 2023-2033

        7.3.1. North America

        7.3.2. Latin America

        7.3.3. Europe

        7.3.4. South Asia & Pacific

        7.3.5. East Asia

        7.3.6. MEA

    7.4. Market Attractiveness Analysis By Region

8. North America Market Analysis 2018-2022 and Forecast 2023-2033, By Country

    8.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2018-2022

    8.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2023-2033

        8.2.1. By Country

            8.2.1.1. U.S.

            8.2.1.2. Canada

        8.2.2. By Drug Type

        8.2.3. By Distribution Channel

    8.3. Market Attractiveness Analysis

        8.3.1. By Country

        8.3.2. By Drug Type

        8.3.3. By Distribution Channel

    8.4. Key Takeaways

9. Latin America Market Analysis 2018-2022 and Forecast 2023-2033, By Country

    9.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2018-2022

    9.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2023-2033

        9.2.1. By Country

            9.2.1.1. Brazil

            9.2.1.2. Mexico

            9.2.1.3. Rest of Latin America

        9.2.2. By Drug Type

        9.2.3. By Distribution Channel

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Drug Type

        9.3.3. By Distribution Channel

    9.4. Key Takeaways

10. Europe Market Analysis 2018-2022 and Forecast 2023-2033, By Country

    10.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2018-2022

    10.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2023-2033

        10.2.1. By Country

            10.2.1.1. Germany

            10.2.1.2. U.K.

            10.2.1.3. France

            10.2.1.4. Spain

            10.2.1.5. Italy

            10.2.1.6. Rest of Europe

        10.2.2. By Drug Type

        10.2.3. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Type

        10.3.3. By Distribution Channel

    10.4. Key Takeaways

11. South Asia & Pacific Market Analysis 2018-2022 and Forecast 2023-2033, By Country

    11.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2018-2022

    11.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2023-2033

        11.2.1. By Country

            11.2.1.1. India

            11.2.1.2. Malaysia

            11.2.1.3. Singapore

            11.2.1.4. Thailand

            11.2.1.5. Australia

            11.2.1.6. New Zealand

            11.2.1.7. Rest of South Asia & Pacific

        11.2.2. By Drug Type

        11.2.3. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Type

        11.3.3. By Distribution Channel

    11.4. Key Takeaways

12. East Asia Market Analysis 2018-2022 and Forecast 2023-2033, By Country

    12.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2018-2022

    12.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2023-2033

        12.2.1. By Country

            12.2.1.1. China

            12.2.1.2. Japan

            12.2.1.3. South Korea

        12.2.2. By Drug Type

        12.2.3. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug Type

        12.3.3. By Distribution Channel

    12.4. Key Takeaways

13. MEA Market Analysis 2018-2022 and Forecast 2023-2033, By Country

    13.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2018-2022

    13.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2023-2033

        13.2.1. By Country

            13.2.1.1. GCC Countries

            13.2.1.2. South Africa

            13.2.1.3. Israel

            13.2.1.4. Rest of MEA

        13.2.2. By Drug Type

        13.2.3. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Drug Type

        13.3.3. By Distribution Channel

    13.4. Key Takeaways

14. Key Countries Market Analysis

    14.1. U.S.

        14.1.1. Pricing Analysis

        14.1.2. Market Share Analysis, 2022

            14.1.2.1. By Drug Type

            14.1.2.2. By Distribution Channel

    14.2. Canada

        14.2.1. Pricing Analysis

        14.2.2. Market Share Analysis, 2022

            14.2.2.1. By Drug Type

            14.2.2.2. By Distribution Channel

    14.3. Brazil

        14.3.1. Pricing Analysis

        14.3.2. Market Share Analysis, 2022

            14.3.2.1. By Drug Type

            14.3.2.2. By Distribution Channel

    14.4. Mexico

        14.4.1. Pricing Analysis

        14.4.2. Market Share Analysis, 2022

            14.4.2.1. By Drug Type

            14.4.2.2. By Distribution Channel

    14.5. Germany

        14.5.1. Pricing Analysis

        14.5.2. Market Share Analysis, 2022

            14.5.2.1. By Drug Type

            14.5.2.2. By Distribution Channel

    14.6. U.K.

        14.6.1. Pricing Analysis

        14.6.2. Market Share Analysis, 2022

            14.6.2.1. By Drug Type

            14.6.2.2. By Distribution Channel

    14.7. France

        14.7.1. Pricing Analysis

        14.7.2. Market Share Analysis, 2022

            14.7.2.1. By Drug Type

            14.7.2.2. By Distribution Channel

    14.8. Spain

        14.8.1. Pricing Analysis

        14.8.2. Market Share Analysis, 2022

            14.8.2.1. By Drug Type

            14.8.2.2. By Distribution Channel

    14.9. Italy

        14.9.1. Pricing Analysis

        14.9.2. Market Share Analysis, 2022

            14.9.2.1. By Drug Type

            14.9.2.2. By Distribution Channel

    14.10. India

        14.10.1. Pricing Analysis

        14.10.2. Market Share Analysis, 2022

            14.10.2.1. By Drug Type

            14.10.2.2. By Distribution Channel

    14.11. Malaysia

        14.11.1. Pricing Analysis

        14.11.2. Market Share Analysis, 2022

            14.11.2.1. By Drug Type

            14.11.2.2. By Distribution Channel

    14.12. Singapore

        14.12.1. Pricing Analysis

        14.12.2. Market Share Analysis, 2022

            14.12.2.1. By Drug Type

            14.12.2.2. By Distribution Channel

    14.13. Thailand

        14.13.1. Pricing Analysis

        14.13.2. Market Share Analysis, 2022

            14.13.2.1. By Drug Type

            14.13.2.2. By Distribution Channel

    14.14. China

        14.14.1. Pricing Analysis

        14.14.2. Market Share Analysis, 2022

            14.14.2.1. By Drug Type

            14.14.2.2. By Distribution Channel

    14.15. Japan

        14.15.1. Pricing Analysis

        14.15.2. Market Share Analysis, 2022

            14.15.2.1. By Drug Type

            14.15.2.2. By Distribution Channel

    14.16. South Korea

        14.16.1. Pricing Analysis

        14.16.2. Market Share Analysis, 2022

            14.16.2.1. By Drug Type

            14.16.2.2. By Distribution Channel

    14.17. Australia

        14.17.1. Pricing Analysis

        14.17.2. Market Share Analysis, 2022

            14.17.2.1. By Drug Type

            14.17.2.2. By Distribution Channel

    14.18. New Zealand

        14.18.1. Pricing Analysis

        14.18.2. Market Share Analysis, 2022

            14.18.2.1. By Drug Type

            14.18.2.2. By Distribution Channel

    14.19. GCC Countries

        14.19.1. Pricing Analysis

        14.19.2. Market Share Analysis, 2022

            14.19.2.1. By Drug Type

            14.19.2.2. By Distribution Channel

    14.20. South Africa

        14.20.1. Pricing Analysis

        14.20.2. Market Share Analysis, 2022

            14.20.2.1. By Drug Type

            14.20.2.2. By Distribution Channel

    14.21. Israel

        14.21.1. Pricing Analysis

        14.21.2. Market Share Analysis, 2022

            14.21.2.1. By Drug Type

            14.21.2.2. By Distribution Channel

15. Market Structure Analysis

    15.1. Competition Dashboard

    15.2. Competition Benchmarking

    15.3. Market Share Analysis of Top Players

        15.3.1. By Regional

        15.3.2. By Drug Type

        15.3.3. By Distribution Channel

16. Competition Analysis

    16.1. Competition Deep Dive

        16.1.1. Eli Lilly Company

            16.1.1.1. Overview

            16.1.1.2. Product Portfolio

            16.1.1.3. Profitability by Market Segments

            16.1.1.4. Sales Footprint

            16.1.1.5. Strategy Overview

                16.1.1.5.1. Marketing Strategy

        16.1.2. GlaxoSmithKline

            16.1.2.1. Overview

            16.1.2.2. Product Portfolio

            16.1.2.3. Profitability by Market Segments

            16.1.2.4. Sales Footprint

            16.1.2.5. Strategy Overview

                16.1.2.5.1. Marketing Strategy

        16.1.3. Pfizer Inc.

            16.1.3.1. Overview

            16.1.3.2. Product Portfolio

            16.1.3.3. Profitability by Market Segments

            16.1.3.4. Sales Footprint

            16.1.3.5. Strategy Overview

                16.1.3.5.1. Marketing Strategy

        16.1.4. Janssen Pharmaceuticals

            16.1.4.1. Overview

            16.1.4.2. Product Portfolio

            16.1.4.3. Profitability by Market Segments

            16.1.4.4. Sales Footprint

            16.1.4.5. Strategy Overview

                16.1.4.5.1. Marketing Strategy

        16.1.5. AbbVie Inc.

            16.1.5.1. Overview

            16.1.5.2. Product Portfolio

            16.1.5.3. Profitability by Market Segments

            16.1.5.4. Sales Footprint

            16.1.5.5. Strategy Overview

                16.1.5.5.1. Marketing Strategy

        16.1.6. AstraZeneca

            16.1.6.1. Overview

            16.1.6.2. Product Portfolio

            16.1.6.3. Profitability by Market Segments

            16.1.6.4. Sales Footprint

            16.1.6.5. Strategy Overview

                16.1.6.5.1. Marketing Strategy

        16.1.7. H. Lundbeck

            16.1.7.1. Overview

            16.1.7.2. Product Portfolio

            16.1.7.3. Profitability by Market Segments

            16.1.7.4. Sales Footprint

            16.1.7.5. Strategy Overview

                16.1.7.5.1. Marketing Strategy

        16.1.8. Sandoz International GmbH

            16.1.8.1. Overview

            16.1.8.2. Product Portfolio

            16.1.8.3. Profitability by Market Segments

            16.1.8.4. Sales Footprint

            16.1.8.5. Strategy Overview

                16.1.8.5.1. Marketing Strategy

        16.1.9. Par Pharmaceutical Companies Inc.

            16.1.9.1. Overview

            16.1.9.2. Product Portfolio

            16.1.9.3. Profitability by Market Segments

            16.1.9.4. Sales Footprint

            16.1.9.5. Strategy Overview

                16.1.9.5.1. Marketing Strategy

        16.1.10. Otsuka Holdings Co. Ltd.

            16.1.10.1. Overview

            16.1.10.2. Product Portfolio

            16.1.10.3. Profitability by Market Segments

            16.1.10.4. Sales Footprint

            16.1.10.5. Strategy Overview

                16.1.10.5.1. Marketing Strategy

17. Assumptions & Acronyms Used

18. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 1: Global Market Value (US$ Bn) Forecast by Region, 2018-2033

Table 2: Global Market Value (US$ Bn) Forecast by Drug Type, 2018-2033

Table 3: Global Market Value (US$ Bn) Forecast by Distribution Channel, 2018-2033

Table 4: North America Market Value (US$ Bn) Forecast by Country, 2018-2033

Table 5: North America Market Value (US$ Bn) Forecast by Drug Type, 2018-2033

Table 6: North America Market Value (US$ Bn) Forecast by Distribution Channel, 2018-2033

Table 7: Latin America Market Value (US$ Bn) Forecast by Country, 2018-2033

Table 8: Latin America Market Value (US$ Bn) Forecast by Drug Type, 2018-2033

Table 9: Latin America Market Value (US$ Bn) Forecast by Distribution Channel, 2018-2033

Table 10: Europe Market Value (US$ Bn) Forecast by Country, 2018-2033

Table 11: Europe Market Value (US$ Bn) Forecast by Drug Type, 2018-2033

Table 12: Europe Market Value (US$ Bn) Forecast by Distribution Channel, 2018-2033

Table 13: South Asia & Pacific Market Value (US$ Bn) Forecast by Country, 2018-2033

Table 14: South Asia & Pacific Market Value (US$ Bn) Forecast by Drug Type, 2018-2033

Table 15: South Asia & Pacific Market Value (US$ Bn) Forecast by Distribution Channel, 2018-2033

Table 16: East Asia Market Value (US$ Bn) Forecast by Country, 2018-2033

Table 17: East Asia Market Value (US$ Bn) Forecast by Drug Type, 2018-2033

Table 18: East Asia Market Value (US$ Bn) Forecast by Distribution Channel, 2018-2033

Table 19: MEA Market Value (US$ Bn) Forecast by Country, 2018-2033

Table 20: MEA Market Value (US$ Bn) Forecast by Drug Type, 2018-2033

Table 21: MEA Market Value (US$ Bn) Forecast by Distribution Channel, 2018-2033

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 1: Global Market Value (US$ Bn) by Drug Type, 2023-2033

Figure 2: Global Market Value (US$ Bn) by Distribution Channel, 2023-2033

Figure 3: Global Market Value (US$ Bn) by Region, 2023-2033

Figure 4: Global Market Value (US$ Bn) Analysis by Region, 2018-2033

Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023-2033

Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023-2033

Figure 7: Global Market Value (US$ Bn) Analysis by Drug Type, 2018-2033

Figure 8: Global Market Value Share (%) and BPS Analysis by Drug Type, 2023-2033

Figure 9: Global Market Y-o-Y Growth (%) Projections by Drug Type, 2023-2033

Figure 10: Global Market Value (US$ Bn) Analysis by Distribution Channel, 2018-2033

Figure 11: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2023-2033

Figure 12: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023-2033

Figure 13: Global Market Attractiveness by Drug Type, 2023-2033

Figure 14: Global Market Attractiveness by Distribution Channel, 2023-2033

Figure 15: Global Market Attractiveness by Region, 2023-2033

Figure 16: North America Market Value (US$ Bn) by Drug Type, 2023-2033

Figure 17: North America Market Value (US$ Bn) by Distribution Channel, 2023-2033

Figure 18: North America Market Value (US$ Bn) by Country, 2023-2033

Figure 19: North America Market Value (US$ Bn) Analysis by Country, 2018-2033

Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023-2033

Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023-2033

Figure 22: North America Market Value (US$ Bn) Analysis by Drug Type, 2018-2033

Figure 23: North America Market Value Share (%) and BPS Analysis by Drug Type, 2023-2033

Figure 24: North America Market Y-o-Y Growth (%) Projections by Drug Type, 2023-2033

Figure 25: North America Market Value (US$ Bn) Analysis by Distribution Channel, 2018-2033

Figure 26: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023-2033

Figure 27: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023-2033

Figure 28: North America Market Attractiveness by Drug Type, 2023-2033

Figure 29: North America Market Attractiveness by Distribution Channel, 2023-2033

Figure 30: North America Market Attractiveness by Country, 2023-2033

Figure 31: Latin America Market Value (US$ Bn) by Drug Type, 2023-2033

Figure 32: Latin America Market Value (US$ Bn) by Distribution Channel, 2023-2033

Figure 33: Latin America Market Value (US$ Bn) by Country, 2023-2033

Figure 34: Latin America Market Value (US$ Bn) Analysis by Country, 2018-2033

Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023-2033

Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023-2033

Figure 37: Latin America Market Value (US$ Bn) Analysis by Drug Type, 2018-2033

Figure 38: Latin America Market Value Share (%) and BPS Analysis by Drug Type, 2023-2033

Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Drug Type, 2023-2033

Figure 40: Latin America Market Value (US$ Bn) Analysis by Distribution Channel, 2018-2033

Figure 41: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023-2033

Figure 42: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023-2033

Figure 43: Latin America Market Attractiveness by Drug Type, 2023-2033

Figure 44: Latin America Market Attractiveness by Distribution Channel, 2023-2033

Figure 45: Latin America Market Attractiveness by Country, 2023-2033

Figure 46: Europe Market Value (US$ Bn) by Drug Type, 2023-2033

Figure 47: Europe Market Value (US$ Bn) by Distribution Channel, 2023-2033

Figure 48: Europe Market Value (US$ Bn) by Country, 2023-2033

Figure 49: Europe Market Value (US$ Bn) Analysis by Country, 2018-2033

Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2023-2033

Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2023-2033

Figure 52: Europe Market Value (US$ Bn) Analysis by Drug Type, 2018-2033

Figure 53: Europe Market Value Share (%) and BPS Analysis by Drug Type, 2023-2033

Figure 54: Europe Market Y-o-Y Growth (%) Projections by Drug Type, 2023-2033

Figure 55: Europe Market Value (US$ Bn) Analysis by Distribution Channel, 2018-2033

Figure 56: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023-2033

Figure 57: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023-2033

Figure 58: Europe Market Attractiveness by Drug Type, 2023-2033

Figure 59: Europe Market Attractiveness by Distribution Channel, 2023-2033

Figure 60: Europe Market Attractiveness by Country, 2023-2033

Figure 61: South Asia & Pacific Market Value (US$ Bn) by Drug Type, 2023-2033

Figure 62: South Asia & Pacific Market Value (US$ Bn) by Distribution Channel, 2023-2033

Figure 63: South Asia & Pacific Market Value (US$ Bn) by Country, 2023-2033

Figure 64: South Asia & Pacific Market Value (US$ Bn) Analysis by Country, 2018-2033

Figure 65: South Asia & Pacific Market Value Share (%) and BPS Analysis by Country, 2023-2033

Figure 66: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Country, 2023-2033

Figure 67: South Asia & Pacific Market Value (US$ Bn) Analysis by Drug Type, 2018-2033

Figure 68: South Asia & Pacific Market Value Share (%) and BPS Analysis by Drug Type, 2023-2033

Figure 69: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Drug Type, 2023-2033

Figure 70: South Asia & Pacific Market Value (US$ Bn) Analysis by Distribution Channel, 2018-2033

Figure 71: South Asia & Pacific Market Value Share (%) and BPS Analysis by Distribution Channel, 2023-2033

Figure 72: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023-2033

Figure 73: South Asia & Pacific Market Attractiveness by Drug Type, 2023-2033

Figure 74: South Asia & Pacific Market Attractiveness by Distribution Channel, 2023-2033

Figure 75: South Asia & Pacific Market Attractiveness by Country, 2023-2033

Figure 76: East Asia Market Value (US$ Bn) by Drug Type, 2023-2033

Figure 77: East Asia Market Value (US$ Bn) by Distribution Channel, 2023-2033

Figure 78: East Asia Market Value (US$ Bn) by Country, 2023-2033

Figure 79: East Asia Market Value (US$ Bn) Analysis by Country, 2018-2033

Figure 80: East Asia Market Value Share (%) and BPS Analysis by Country, 2023-2033

Figure 81: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023-2033

Figure 82: East Asia Market Value (US$ Bn) Analysis by Drug Type, 2018-2033

Figure 83: East Asia Market Value Share (%) and BPS Analysis by Drug Type, 2023-2033

Figure 84: East Asia Market Y-o-Y Growth (%) Projections by Drug Type, 2023-2033

Figure 85: East Asia Market Value (US$ Bn) Analysis by Distribution Channel, 2018-2033

Figure 86: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023-2033

Figure 87: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023-2033

Figure 88: East Asia Market Attractiveness by Drug Type, 2023-2033

Figure 89: East Asia Market Attractiveness by Distribution Channel, 2023-2033

Figure 90: East Asia Market Attractiveness by Country, 2023-2033

Figure 91: MEA Market Value (US$ Bn) by Drug Type, 2023-2033

Figure 92: MEA Market Value (US$ Bn) by Distribution Channel, 2023-2033

Figure 93: MEA Market Value (US$ Bn) by Country, 2023-2033

Figure 94: MEA Market Value (US$ Bn) Analysis by Country, 2018-2033

Figure 95: MEA Market Value Share (%) and BPS Analysis by Country, 2023-2033

Figure 96: MEA Market Y-o-Y Growth (%) Projections by Country, 2023-2033

Figure 97: MEA Market Value (US$ Bn) Analysis by Drug Type, 2018-2033

Figure 98: MEA Market Value Share (%) and BPS Analysis by Drug Type, 2023-2033

Figure 99: MEA Market Y-o-Y Growth (%) Projections by Drug Type, 2023-2033

Figure 100: MEA Market Value (US$ Bn) Analysis by Distribution Channel, 2018-2033

Figure 101: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2023-2033

Figure 102: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023-2033

Figure 103: MEA Market Attractiveness by Drug Type, 2023-2033

Figure 104: MEA Market Attractiveness by Distribution Channel, 2023-2033

Figure 105: MEA Market Attractiveness by Country, 2023-2033

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Anxiety Disorders And Depression Treatment Market

Published : November 2022

Healthcare

Drug Free Depression Treatment Market

Published : March 2019

Healthcare

Depression Drugs Market

Published : March 2017

Google translate

Treatment-Resistant Depression Treatment Market